Key Highlights
- Daniel Janse, Ph.D., appointed President and CEO of AffyImmune.
- Dr. Janse brings 20 years of biopharmaceutical expertise.
- Focus on advancing CAR T cell therapies for solid tumors.
- Successful Phase 1 study with complete response in advanced thyroid cancer.
Source: Business Wire
Notable Quotes
- “We are thrilled to welcome Dr. Janse as the new CEO of AffyImmune. His extensive experience in the biotech industry and his proven leadership in driving innovation and strategic growth make him the ideal executive to lead AffyImmune into its next phase of growth. We have full confidence in his ability to advance our mission of bringing CAR T cell therapies to patients with solid tumors.” — Simone Song, Founding Partner, ORI Capital and Board Director at AffyImmune
- “I am honored to join AffyImmune at such a pivotal time in the company’s journey. I look forward to working with the team and Board of Directors to continue and expedite the development of AIC100 for patients with advanced thyroid cancers and non-small-cell lung cancer. The unique ability for AffyImmune to target ICAM-1 using an affinity-tuned LFA-1 binder and to track AIC100 after administration to patients are exciting scientific breakthroughs that can transform the sector.” — Dr. Daniel Janse, Chief Executive Officer at AffyImmune
SoHC's Take
The appointment of Dr. Daniel Janse as President and CEO of AffyImmune marks a significant milestone for the company. Dr. Janse’s extensive background in biopharmaceutical research and his leadership experience are well-aligned with AffyImmune’s mission to advance CAR T cell therapies for solid tumors. His track record in driving innovation and strategic growth will be invaluable as AffyImmune progresses its pipeline, especially following the promising results from its Phase 1 study of AIC100 in advanced thyroid cancer. This leadership change is poised to accelerate the development and potential market introduction of novel CAR T therapies, addressing critical needs in cancer treatment.
